MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.

The move to reclassify cannabis from a Schedule I to a Schedule III drug could spark new studies into pain, aging and women's health, Dr. Staci Gruber tells GBH's All Things Considered.

A pill version of the popular GLP-1 weight-loss drug Wegovy has been green-lit for use in the U.S. Here’s what that means for ...

President Donald Trump just signed an executive order that reclassified marijuana from a Schedule I narcotic to Schedule III.

After two decades of chart-topping hits, Michael landed his first and only Christmas number one with the environmental anthem ...

On Dec. 18, Trump ordered the government to stop classifying marijuana as a Schedule I drug, a designation that includes the ...

President Donald Trump is considering an executive order aimed at easing federal marijuana restrictions, according to reports by The Washington Post and CNBC, in a move that would make it easier to ...

More than 1,200 ‘slap on the wrist’ warnings were handed out by police last year to people caught with Class A drugs - allowing them to escape without punishment. Ministers were condemned for forcing ...

Scientists have reported the discovery of the first in a promising new class of antibiotics — and the find was unexpected, as they hadn't set out to find new drugs. The new antibiotic compound shows ...

Researchers from Queen Mary University of London's School of Biological and Behavioral Sciences, using the simple fission yeast as a model, have shown that the new TOR inhibitor rapalink-1 prolongs ...